Metabolic
5-Amino-1MQ
NNMT inhibitor · small molecule · NNMT
A small molecule (not technically a peptide) that inhibits an enzyme linked to fat-cell metabolism — genuinely interesting animal biology, essentially no human trial data.
Reference status
Editorial research · independent review pending · 3 claims graded
What it is
5-Amino-1MQ inhibits NNMT (nicotinamide N-methyltransferase), an enzyme that's been linked in animal studies to fat-cell energy metabolism and body weight regulation. It's grouped with peptides in most community discussion, though chemically it's a small molecule rather than an amino-acid chain.
The animal data (mainly in mice) is genuinely interesting from a metabolic-science standpoint. Human trial data at the doses marketed to consumers is essentially absent, which is an unusually large evidence gap even for this library.
The science, graded
What’s claimed — and how strong the evidence behind each claim actually is.
“Inhibits NNMT to support fat metabolism”
The core mechanism is real and mouse data is promising; NNMT-obesity link is an active research area.
Claim-level citation mapping is in progress.
“Produces meaningful human weight loss”
No published human trial data exists for this claim at consumer doses.
Claim-level citation mapping is in progress.
“Boosts NAD+ levels as a side benefit”
Plausible from the NNMT mechanism (it affects methyl-donor pathways connected to NAD+); not separately confirmed in humans.
Claim-level citation mapping is in progress.
Legal and regulatory context
Separate summaries for Great Britain, the United States, and the European Union. These are preliminary research summaries awaiting independent regional review; they are not legal determinations or advice.
Great Britain
Not a licensed medicine or approved supplement in the UK; sold as a research chemical, with no legal human-use route.
This is preliminary regulatory research, not a reviewed legal determination or legal advice.
United States
Regional legal and regulatory review required before publication.
This is preliminary regulatory research, not a reviewed legal determination or legal advice.
- FDA's Concerns About Unapproved Drugs · U.S. Food and Drug Administration
European Union
Regional legal and regulatory review required before publication.
This is preliminary regulatory research, not a reviewed legal determination or legal advice.
- Buying medicines online · European Medicines Agency
What the community says
A newer entrant to metabolic-peptide discussion, riding some of the same interest as NAD+ and MOTS-c. Even enthusiastic posts tend to acknowledge the almost total absence of human data.
Where they’re talking
- r/PeptidesDiscussed as an 'emerging' compound, evidence caveats usually included.
References
- 1.Supply unlicensed medicinal products (specials) · MHRA
- 2.FDA's Concerns About Unapproved Drugs · U.S. Food and Drug Administration
- 3.Buying medicines online · European Medicines Agency